British Biosimilars Association

BOPA is building links with the British Biosimilars Association BBA.   The BOPA committee is keen to support our members dealing with the work of managing the introduction of biosimilars, and so is talking to the BBA about how we can work togeather can support BOPA members.  

The BBA site is worth a look as it has a good resources section that pull’s togeather a lot of key resources on biosimilars( expect to see BOPA there soon).

BOPA is also starting to work with the manufacturers of e-prescribing systems to see what can be done by the manufacturers to make their systems support the introduction of biosimilars more easily.  I’ll keep you posted as things develop, as we’ve had lots of feedback on the time people face changing their systems to ensure biosimilars are prescribed correctly, i.e. rituxumab (Mabthera) or rituxumab (Truxima) or rituximab (Rixathon) and recreasting multiple protocols, so BOPA is keen to push for key stakeholders to work togeather to make it easier.

Latest News

By Suriya Marshall on 14th March 2026

Parliamentary Intervention Sparks National Campaign to Protect NHS Staff from Hazardous Medicinal Products (HMPs)

First UK Campaign to Protect Healthcare Workers from Exposure to Hazardous Medicinal Products (HMPs) launches in Westminster London, 10 March 2026: Today, the Safer Healthcare and Biosafety Network (SHBN) launches…

Read article
By Suriya Marshall on 14th March 2026

Clinical Pharmacy Congress. 8th-9th May 2026

Dear BOPA member, We are excited to announce that we have partnered with Clinical Pharmacy Congress 2026. Clinical Pharmacy Congress is the UK’s leading event for clinical pharmacy professionals working across…

Read article
By BOPA Executive Committee on 13th March 2026

First UK Campaign to Protect Healthcare Workers from Exposure to Hazardous Medicinal Products (HMPs) launches in Westminster

London, 10 March 2026: The Safer Healthcare and Biosafety Network (SHBN) launches a new campaign titled “Protecting Healthcare Workers: Safer Handling of Hazardous Medicinal Products” to raise awareness of the dangers…

Read article
By BOPA on 13th March 2026

Invitation to Participate: SWEET-PLUS Study

You are invited to take part in a research study called SWEET-PLUS (NIHR Research for Patient Benefit: 207952), run by Newcastle and Oxford Brookes Universities. SWEET-PLUS aims to understand experiences…

Read article